Precision BioSciences Inc (DTIL)

[MI Dendream]

I know the numbers are small, but the ORR for heavily pretreated r/rNHL that had previously received CAR-T (75%) and Stem Cell Transplantation (66%) is pretty impressive. They are focusing on eLD to delay immune response to CAR-T administration, but I think they are still looking at retreatment. Combining the two approaches could produce some strong long term results in these difficult to save patients.

Precision is leading the race to allogenic off-the-shelf CAR-T with solid phase I results. How CRSP is worth $6B and this company is only priced out at $650M is beyond me to understand. DTIL is looking at potentially $2.5B in milestone payments on the gene editing program, has $200M cash on hand and has one heck of an exciting pipeline and platforms.